

PRE-CONFERENCE WORKSHOP

WEDNESDAY 27 SEPTEMBER 2023

09:00-13:00 MDR in AML

Workshop organisers: Willemijn Hobo (Nijmegen, The Netherlands) and Francesco Buccisano (Rome, Italy)

Level: Advanced. Max. 20 places.

Choice and intensity of treatment of acute myeloid leukemia (AML) patients is based on prognostic risk classification. One of the most important prognostic factors in AML is measurable residual disease (MRD) after intensive chemotherapy. Hence, AML-MRD evaluation has been incorporated in clinical practice to select the appropriate consolidation treatment. Although molecular techniques are available, flow cytometry is the most commonly technique used for AML-MRD assessment. In this course we will present the European Leukemia Net guidelines, discuss the pros and cons of external quality assessment, provide details on key aspects of the pre-analytical phase, and conclude with a hands-on practical session.

09:00-09:30	ELN Guidelines, recap and future perspectives	Francisco Buccisano (Rome, IT)
09:30-10:00	EQA in MRD: pros and cons	Sylvie Freeman (Birmingham, UK)
10:00-10:30	The importance of preanalytical phase and fluorochrome selection	Tobias Mätzig (Hannover, DE)
10:30-11:00	<i>Coffee break</i>	
11:00-12:00	Practical Session 1	Willemijn Scholten (Amsterdam, NL) and Willemijn Hobo (Nijmegen, NL)
12:00-13:00	Practical session 2	Willemijn Scholten (Amsterdam, NL) and Willemijn Hobo (Nijmegen, NL)
<i>Lunch on your own</i>		
14:00	Start ESCCA Conference	